Coya Therapeutics, Inc. (COYA) Form 8-K — May 12, 2026
$COYAForm 8-KItems 2.02, 8.01, 9.01Filed May 12, 2026, 7:39 AM ET0001193125-26-218198Original filing
Coya Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2026, with a net loss of $7.2 million, in line with the net loss of $7.3 million reported in the same period of 2025. The company's cash and cash equivalents increased to $50.7 million from $46.8 million at the end of 2025, reflecting a recent $11.1 million private placement led by Dr. Reddy’s Laboratories, Inc.
Key figures
- Revenue
- 251147
- Total Debt
- 4300739
- Cash Position
- 50724643
- Shares Outstanding
- 23457183
Price after filing
1 day: +5.8%7 days: +6.5%30 days: +2.8%
Close on the filing date to close N calendar days later (from $4.29). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.